spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

12th Annual Parallel Trade

6-7 February 2018
Holiday Inn Kensington Forum, London, UK

 

SMi Group is proud to announce the return of Europe’s only Parallel Trade conference. Back for the 12thyear, Parallel Trade returns to London on 6th-7th February 2018.

 

Over the years, the European Single market has allowed for pharmaceuticals to be imported and exported freely between member states without the permission of the manufacturers. However, with the arrival of Brexit and guidelines to immanently enforce the Falsified Medicines Directive (FMD) by 2019, the market for pharmaceutical parallel trade is changing.

 

Join us as we discuss the latest changes to regulation, their implementation and major court cases in intellectual property influencing distribution practices. We will also be exploring the safety of patients in relation to the surge in pharmaceutical E-commerce and ways in which currency fluctuations are likely to disrupt the flow of drugs to certain countries in the EU and beyond.

 

With huge interest from leaders in the field, we have worked closely with an expert panel of speakers to present an agenda that is shaping up to be the best Parallel Trade event. This year's event will continue to lead with its unrivalled panel of experts bringing you the most insightful presentations from our confirmed Industry-leading speakers:

 
  • Antonio Mendonca Alves, CEO, Md Pharma Sa
  • Christopher Stothers, Partner, Arnold And Porter Kaye Scholer Llp
  • Darragh O'loughlin, Secretary General, Irish Pharmacy Union
  • Eric Noehrenberg, President, Noehrenberg International Policy Consulting
  • Fabrizio Gianfrate, Professor of Health Economics, University of Ferrara
  • Farasat Bokhari, Senior Lecturer in Economics, Uea, University of East Anglia
  • Felipe Florez-Arango, Head of Finance, Europe, Shire
  • Frank Weissenfeldt, Senior Manager, Supplier Relations, Quintilesims
  • Heinz Kobelt, Director European Affairs, European Association of Euro-Pharmaceutical Companies
  • Ian Walker, Chairman, Epilepsy Action
  • Janice Haigh, VP Pricing & Market Access, Parexel
  • John Jolley, Managing Director, Pharmaconsult Global Ltd
  • Mikas Rimantas, Business Development Director, Lexano
  • Werner Berg, Partner, Baker & Mckenzie
 

Parallel Trade will address short term versus long term concerns of pharmaceutical manufacturers, regulators, parallel traders and patient associations.

 

The 2018 Parallel Trade conference will cover the important issues of:

 
  • Maintaining the integrity of the supply chain
  • Addressing recent developments concerning intellectual property and regulatory law
  • Forecasting currency fluctuations across the single market and the affect this might have on drug shortages, prices and patient accessibility
  • Exploring how Brexit will impact pharmaceutical trade and
    market access in Europe
  • Providing an insight into current anti-trust investigations from industry leaders and the consequences this could have on pharmaceutical parallel trade
 

 

 
 
Print this page
Send to a friend
   
spacer
Industry Events

Clinical Operations in Oncology Trials West Coast

17-18 November 2020, Hilton San Francisco Airport Bayfront

Clinical Operations in Oncology Trials West Coast will be returning this April for another 2 day event full of thought-provoking presentations, discussions and roundtables. This years' conference highlights include the high-level, interactive immuno-oncology discussion panel where specialists from Shasta Bio Ventures, Abbvie and BeiGene shared their top tips on how to run successful and impactful immuno-oncology studies.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>


News and Press Releases

Symphony Health to provide free access to new Metys COVID-19 Module for U.S. based life sciences industry during pandemic

RALEIGH, N.C., April 08, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today that Symphony Health, a PRA Health Sciences company, will make a 30-day license of its newly released MetysTM COVID-19 Module available to the U.S. life science industry at no charge.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement